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ABSTRACT: Ispinesib is a potent inhibitor of kinesin spindle
protein (KSP), which has been identified as a promising target for
antimitotic anticancer drugs. Herein, we report the synthesis of half-
sandwich complexes of Ru, Os, Rh, and Ir bearing the ispinesib-
derived N,N-bidentate ligands (R)- and (S)-2-(1-amino-2-methyl-
propyl)-3-benzyl-7-chloroquinazolin-4(3H)-one and studies on their
chemical and biological properties. Using the enantiomerically pure
(R)- and (S)-forms of the ligand, depending on the organometallic
moiety, either the SM,R or RM,S diastereomers, respectively, were
observed in the molecular structures of the Ru- and Os(cym) (cym
= η6-p-cymene) compounds, whereas the RM,R or SM,S diastereo-
mers were found for the Rh- and Ir(Cp*) (Cp* = η5-
pentamethylcyclopentadienyl) derivatives. However, density func-
tional theory (DFT) calculations suggest that the energy difference
between the diastereomers is very small, and therefore a mixture of both will be present in solution. The organometallics exhibited
varying antiproliferative activity in a series of human cancer cell lines, with the complexes featuring the (R)-enantiomer of the ligand
being more potent than the (S)-configured counterparts. Notably, the Rh and Ir complexes demonstrated high KSP inhibitory
activity, even at 1 nM concentration, which was independent of the chirality of the ligand, whereas the Ru and especially the Os
derivatives were much less active.
■ INTRODUCTION
Undoubtedly, there has been considerable progress in
contemporary cancer medicine, but many tumor types are
still difficult to treat. Commonly used anticancer drugs, such as
tubulin binding agents, taxanes (e.g., paclitaxel, docetaxel),1−5
and Vinca alkaloids (vincristine and vinblastine)6 exhibit
numerous side effects.7 Therefore, it is crucial to develop
new compounds exhibiting fewer or, ideally, no side effects.
This can be achieved through applying a variety of strategies,
such as structural modification of tubulin-binding agents or
design of new low molecular weight inhibitors of proteins
involved in cell division. A vast number of antimitotic agents
have been synthesized8−12 or isolated from natural sources,13
and their biological properties have been extensively evaluated.
To date, however, only a few semisynthetic antimitotic agents
are used for cancer treatment, while others are currently in
clinical trials.14−16
Mitosis, which is a strictly regulated multistep process, can
be disturbed at different stages by selective inhibitors of cell
cycle regulators (e.g., polo-like kinase 1, PLK1)17 or spindle
checkpoint proteins (e.g., Aurora A, Aurora B, CENP-E,
KSP).18−20 The therapeutic potential of inhibitors targeting
aurora A (e.g., PHA-739358, MLN8237),18 aurora B (e.g., PF-
03814735, AZD1152),18 and PLK1 (e.g., BI2536, ON
01910)21,22 is relatively well established. Kinesins (e.g., KSP
and CENPE) have been explored as molecular targets in
cancer therapy since 1999, when the first low molecular weight
inhibitor of a kinesin spindle protein (KSP, also known as
kinesin-5 or Eg5), monastrol, was discovered.23 KSP is a
member of the motor proteins, playing a crucial role in spindle
pole separation. It is highly active in dividing cells while almost
undetectable in nondividing cells. As its inhibition results in
mitotic catastrophe and leads to apoptosis, KSP is a promising
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molecular target for modern antimitotic anticancer drugs. A
large number of structurally diverse molecules have been
identified as KSP inhibitors, and some have entered clinical
trials.24−26 The most active KSP inhibitors include MK-0731,24
ARRY-649,27,28 ispinesib,28,29 and its chromone analogue SB-
743921.29
The tremendous progress in bioorganometallic chemistry
has resulted in a large number of new compounds of unusual
biological activity, for example, by combining organometallic
compounds with biologically active molecules.30,31 Such
conjugates are often more potent antiproliferative agents
than their parent compounds and sometimes exhibit additional
biological properties. To date, the most intensively studied
derivatives are sandwich31 (mainly ferrocene and ruthenocene)
and half-sandwich derivatives of Ru,32,33 Os,33,34 Rh,35 and
Ir.35 We and others studied the influence of organometallic
moieties on the biological activity of antimitotic tubulin-
binding agents such as taxanes,36,37 colchicine,38−41 plinabu-
lin,11 or podophyllotoxin.42,43 We found that replacing the N-
benzoyl moiety of paclitaxel with a ferrocenoyl moiety
significantly increases its ability to induce polymerization of
tubulin and the antiproliferative potency of such conjugates is
higher than that of the parental taxane.36,37,44 In the case of
plinabulin, we found that replacing the phenyl moiety with
ferrocene leads to compounds able to inhibit clinically relevant
multidrug resistance transporters ABCB1 and ABCG2.11
The observed unexpected positive impact of an organo-
metallic moiety on the biological activity of antimitotic agents
encouraged us to study organometallic conjugates of the
potent KSP inhibitor ispinesib 1. Herein, we report new half-
sandwich complexes of Ru, Os, Rh, and Ir bearing 2-(1-amino-
2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one 2
found in ispinesib as an N,N-bidentate ligand showing
inhibitory activity of KSP and potent cytotoxic activity.
■ EXPERIMENTAL SECTION
Materials and Methods. All the reactions were carried out under
inert conditions. All the chemicals were of analytical grade and used
without further purification. Methanol and dichloromethane were
dried according to standard procedures. RuCl3·3H2O, OsO4, RhCl3·
xH2O and IrCl3·xH2O were purchased from Precious Metals Online
and Sigma-Aldrich, The dimers bis[dichlorido(η6-p-cymene)-
ruthenium(II)],45 bis[dichlorido(η6-p-cymene)osmium(II)],46 bis-
[dichlorido(η5-pentamethylcyclopentadienyl)rhodium(III)], and bis-
[dichlorido(η5-pentamethylcyclopentadienyl)iridium(III)]47 were
synthesized as described previously. The 2-(1-amino-2-methylprop-
yl)-3-benzyl-7-chloroquinazolin-4(3H)-one ligands (R)-2 and (S)-2
were synthesized according to a reported procedure.48
High-resolution mass spectra were recorded on a Bruker micro-
TOF-Q II electrospray ionization (ESI) mass spectrometer in positive
ion mode. Elemental analyses of the Ru, Rh, and Ir complexes were
carried out on an Exeter Analytical Inc. CE-440 Elemental Analyzer
and those of the Os complexes at the Campbell Microanalytical
Laboratory, University of Otago. 1H and 13C{1H} NMR spectra were
recorded at 294 K on a Bruker Avance III 600 MHz spectrometer at
600.3 MHz for 1H and 150.1 MHz for 13C{1H}. The 1H and 13C{1H}
chemical shifts were calibrated based on the residual 1H and 13C{1H}
solvent peaks, i.e., δ = 7.26 ppm for 1H and 77.0 ppm for 13C in
CDCl3 and δ = 5.31 ppm for
1H and 54.0 ppm for 13C in CD2Cl2.
The UV-vis spectra were recorded at 294 K on a PerkinElmer Lambda
45 spectrometer. The LC-MS analyses were performed on a Shimadzu
HPLC Nexera XR system with a Shimadzu LCMS-2020 detector on a
Kinetex 2.6 μm PS C18 100 Å column (50 × 2.1 mm) using a
MeCN/water 9:1 mixture at 0.7 mL·min−1 as the mobile phase.
General Procedure for the Synthesis of Ru and Os Complexes
3a−4b. (S)-2 or (R)-2 was dissolved in 10 mL of methanol by
sonication for about 5 min. [(cym)MCl2]2 (M = Ru and Os, cym =
η6-p-cymene) was added in one portion to this solution, and the
resulting reaction mixture was stirred overnight at 50 °C. Upon the
addition of NH4PF6, stirring was continued for another 1−2 h, after
which the solvent was removed under reduced pressure. The residue
was dissolved in 20 mL of dry DCM, and the solution was gravity
filtered to remove inorganic salts. The filtrate was reduced in volume
to about 5 mL, and about 30 mL hexane was added. The resulting
solution was kept at 4 °C for 1−2 days to obtain a yellow crystalline
solid, which was filtered and dried to isolate pure products.
[(cym)Ru{(R)-2)}Cl][PF6] (3a). Compound 3 was prepared in 83%
yield (497 mg) by following the general procedure using 269 mg
(0.790 mmol) of (R)-2, 237 mg (0.287 mmol) of [(cym)RuCl2]2, and
1.070 g (6.564 mmol) of NH4PF6.
1H NMR (600.3 MHz, CDCl3, 294
K): δ 8.49 (d, J = 1.9 Hz, 1H, H-8), 8.26 (d, J = 8.5 Hz, 1H, H-5),
7.61 (dd, J = 8.5, 1.9 Hz, 1H, H-6), 7.41 (t, J = 7.4 Hz, 2H, Ph),
7.37−7.33 (m, 3H, Ph), 6.43 (t, J = 9.0 Hz, 1H, NH2), 5.99 (d, J = 6.1
Hz, 1H, CH3C6H4CH(CH3)2), 5.78 (d, J = 5.9 Hz, 1H,
CH3C6H4CH(CH3)2), 5.70 (d, J = 15.5 Hz, 1H, CH2), 5.63 (d, J =
5.9 Hz, 1H, CH3C6H4CH(CH3)2), 5.24 (d, J = 6.1 Hz, 1H,
CH3C6H4CH(CH3)2), 5.12 (td, J = 7.8, 2.8 Hz, 1H CH(NH2)CH-
(CH3)2), 5.10 (d, J = 16.5 Hz, 1H, CH2), 3.15 (t, J = 8.8 Hz, 1H,
NH2), 2.62−2.57 (m, 1H, CH3C6H4CH(CH3)2), 2.35−2.27 (m, 1H,
CH(NH2)CH(CH3)2), 1.55 (s, 3H, CH3C6H4CH(CH3)2), 1.22 (d, J
= 7.0 Hz, 3H, CH(NH2)CH(CH3)2), 1.16 (d, J = 7.0 Hz, 3H,
CH3C6H4CH(CH3)2), 1.09 (d, J = 6.9 Hz, 3H, CH3C6H4CH-
(CH3)2), 0.51 (d, J = 6.9 Hz, 3H, CH(NH2)CH(CH3)2).
13C{1H}
NMR (150.9 MHz, CDCl3, 294 K): δ 165.8 (CO), 159.3 (CAr),
147.3 (CAr), 142.2 (CAr), 133.9 (CPh), 129.7 (C-6), 129.5 (C-8),
129.4 (C-5), 129.2 (CHPh), 128.4 (CHPh), 127.5 (CHPh), 118.8
(CAr), 104.9 (CAr), 97.7 (CAr), 85.2 (CHAr(Cym)), 84.2 (CHAr(Cym)),
82.4 (CHAr(Cym)), 81.0 (CHAr(Cym)), 67.7 (CH(NH2)CH(CH3)2),
49.9 (CH2), 33.0 (CH(NH2)CH(CH3)2), 30.9 (CH3C6H4CH-
(CH3)2), 22.9 (CH3C6H4CH(CH3)2), 21.0 (CH3C6H4CH(CH3)2),
19.2 (CH(NH2)CH(CH3)2), 17.8 (CH3C6H4CH(CH3)2), 15.6
(CH(NH2)CH(CH3)2). Elemental analysis calculated for
C29H34Cl2F6N3OPRu (757.539 g/mol): C, 45.98; H, 4.52; N, 5.55.
Found: C, 45.82; H, 4.59; N, 5.62. ESI-MS calculated for
C29H34Cl2N3ORu [M − PF6]+, m/z: 612.1119. Found: 612.1137.
General Procedure for the Synthesis of Rh and Ir Complexes
5a−6b. A solution of 1 equiv of ligand (R)-2 or (S)-2 in an
appropriate amount of methanol was added to a slurry of 0.5 equiv of
[(Cp*)MCl2]2 (M = Rh or Ir, Cp* = η
5-pentamethylcyclopenta-
dienyl) in 5 mL of methanol, and the resulting solution was stirred at
RT under an argon atmosphere for 1 h. The solvent was evaporated,
and the residue was dissolved in an appropriate amount of water. A
saturated solution of KPF6 (3 mL) in water was added to this
solution. The product was extracted with dichloromethane (3 × 10
mL). The organic fractions were combined and dried over magnesium
sulfate, and the solution was evaporated to dryness. The crude
product was dissolved in a minimal amount of hot methanol, and the
resulting solution was kept in the freezer for 48 h at −30 °C. Crystals
of pure products were collected by filtration, washed with cold
methanol, and dried.
[(Cp*)Rh{(R)-2)}Cl][PF6] (5a). Compound 5a was synthesized in
75% yield (171 mg) according to the general procedure starting from
92 mg (0.15 mmol) of [(Cp*)RhCl2]2 and 103 mg (0.30 mmol) of
(R)-2. 1H NMR (600.3 MHz, CD2Cl2, 294 K): δ 8.29 (d, J = 8.6 Hz,
1H, H-5), 8.25 (d, J = 1.6 Hz, 1H, H-8), 7.64 (dd, J = 8.5, 1.7 Hz, 1H,
H-6), 7.43 (t, J = 7.4 Hz, 2H, Ph), 7.37 (t, J = 7.3 Hz, 1H, Ph), 7.34
(d, J = 7.5 Hz, 2H, Ph), 5.95 (d, J = 15.3 Hz, 1H, CH2), 5.01 (td, J =
7.3, 2.3 Hz, 1H, CH(NH2)CH(CH3)2), 4.89 (d, J = 15.5 Hz, 1H,
CH2), 4.55 (t, J = 8.9 Hz, 1H, NH2), 3.46 (t, J = 8.2 Hz, 1H, NH2),
2.37−2.32 (m, 1H, CH(NH2)CH(CH3)2), 1.42 (s, 15H, Cp*), 1.26
(d, J = 6.9 Hz, 3H, CH(NH2)CH(CH3)2), 0.59 (d, J = 6.9 Hz, 3H,
CH(NH2)CH(CH3)2).
13C{1H} NMR (151.0 MHz, CD2Cl2, 294 K):
δ 166.7 (CO), 160.2 (CAr), 145.6 (CAr), 142.6 (CAr), 135.3 (CAr),
130.2 (C-6), 130.2 (CHPh), 129.9 (C-5), 129.5 (CHPh), 128.2 (CHPh
or C-8), 128.1 (CHPh or C-8), 120.1 (CAr), 96.7 (d,
1JC−Rh = 8.5 Hz,
η5-C5Me5), 65.5 (CH(NH2)CH(CH3)2), 49.3 (CH2), 34.1 (CH-
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(NH2)CH(CH3)2), 19.8 (CH(NH2)CH(CH3)2), 15.7 (CH(NH2)-
CH(CH3)2), 9.2 (CH3(Cp*)). Elemental analysis calculated for
C29H35Cl2F6N3OPRh (760.388 g/mol): C, 45.81; H, 4.64; N, 5.53.
Found: C, 45.51; H, 4.32; N, 5.51. ESI-MS calculated for
C29H35Cl2N3ORh [M - PF6]
+, m/z: 614.1207. Found: 614.1193.
calculated for C29H34ClN3ORh [M - HCl - PF6]
+, m/z: 578.1440.
Found: 578.1435.
■ RESULTS AND DISCUSSION
The half-sandwich complexes 3a−6b were synthesized in one
step reactions starting from optically pure ligands (R)-2 for
3a−6a or (S)-2 for 3b−6b and the corresponding dimetallic
precursors [(cym)MCl2]2 (M = Ru for 3, M = Os for 4) or
[(Cp*)MCl2]2 (M = Rh for 5, M = Ir for 6). All complexes
were prepared in the reaction of enantiomerically pure 2 with
0.5 equiv of the corresponding dimetallic precursors in
methanol at RT or 50 °C and were isolated as hexafluoro-
phosphate salts in good to excellent yields (Chart 1). The
structures of these complexes were established by NMR
spectroscopy, MS, and X-ray crystallography.
The complexation of ligands (R)-2 and (S)-2 to the metal
centers results in significant changes in the NMR spectra. For
example, in the 1H NMR spectra, the H-8 signal resonated at
7.68 ppm in 2, while in case of the complexes the proton was
detected at 8.51, 8.37, 8.26, and 8.20 ppm for 3−6,
respectively. The diastereotopic protons of the NH2 group
coordinated to the metal centers were observed as well-
separated multiplets at 6.41 and 3.16 ppm for 3, at 7.19 and
4.12 ppm for 4, at 4.55 and 3.46 ppm for 5, and at 5.44 and
4.20 ppm for 6.
It might be expected that a mixture of diastereoisomers
would be formed in the complexation reactions of ligands (R)-
and (S)-2; however, only one main set of peaks for each
complex 3a−6b was detected by NMR spectroscopy together
with small amounts of a second species, possibly due to ligand
exchange in solution. The configuration of the products in
CDCl3 or CD2Cl2 solutions was determined by 2D NOE
experiments. For Rh and Ir complexes 5a−6b, key NOE
contacts between Cp* protons and H-8, NH2, and CH3
protons of the aminoisobutyl chain were detected, while for
Ru and Os complexes, contacts between cym aromatic protons
and H-8 and between aminoisobutyl chain and phenyl, amine,
and CH2−benzyl protons were found (Figure 1 for 3b and 5a).
To investigate whether the complexes exist in solution as a
mixture of diastereoisomers, we recorded NMR spectra at a
low temperature in CD2Cl2. As shown in Figure 2 for Rh
complex 5b, decreasing the temperature to 253 K results in the
coalescence of some peaks, e.g., those assigned to the PhCH2
and iPr groups. Lowering the temperature further to 203−
213 K results in the formation of well-separated peaks due to
the low exchange rate. The process was found to be reversible,
and the spectra recorded at RT were identical to the initially
recorded ones. Similar behavior was observed for the other
complexes (Figures S1−S3).
Single crystals suitable for X-ray diffraction analysis were
obtained by slow diffusion of n-hexane into solutions of the Ru
and Os complexes in DCM, while in the case of the Rh and Ir
complexes, crystals were grown by slowly cooling saturated
methanolic solutions, which were stored at −30 °C for 48 h.
The Ru and Os complexes 3b and 4a bearing the (S)-2 and
(R)-2 ligands, respectively, crystallized in the P212121 and P21
space groups. Compounds 5a and 6a and compounds 5b and
6b crystallized in the enantiomorphic pairs of P61 (a) and P65
(b) space groups, respectively. The latter compounds are
isostructural and form analogous crystal lattices in the solid
state.
All of these compounds displayed pseudo-octahedral
geometry at the metal center with the piano-stool config-
uration. As expected, ligands (R)-2 and (S)-2 acted as N,N-
chelators, forming five-membered rings with the metal ions by
coordination through the NH2 nitrogen and N−1 of the
quinazoline moiety (Figures 3 and S4). In all cases, single
diastereomers were isolated with the cym complexes 3b and 4a
showing RRu,S and SOs,R configurations, while in case of the
Cp* compounds 5a, 5b, 6a, and 6b, they were found to be
RM,R or SM,S. In the cym complexes, the arene ligand is in
anticonfiguration to the isopropyl group of the quinazoline
ligand and syn to the benzyl group of the quinazoline ligand,
while it is vice versa for the Rh and Ir complexes with the Cp*
ligands. In neither of the structures were H-bonding or π-
stacking observed. The bond lengths around the metal center
were for all complexes in similar ranges (Table 1). The Rh
derivatives had slightly larger bond lengths from the Rh center
Chart 1. Structure of (R)-Ispinesib 1 and Synthetic Route to Complexes 3a−6b
Figure 1. Stereochemistry of complexes 3b (left) and 5a (right) in
solution. Double arrows indicate key NOE contacts.
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to the endocyclic nitrogen atom than found for Ir and
especially Ru and Os.
In order to explore the foundation for the formation of
crystals from different diastereomers dependent on the π-
bound ligand at the metal center, density functional theory
(DFT) calculations were conducted with Gaussian 09W.
Calculation of the energetic differences in the ground state
between the Ru and Rh complexes (3a, 3b, 5a, and 5b, Table
S2) and dependent on the enantiomer of ligand 2 revealed that
the energies were very similar for the stereoisomers of the
different metal centers (Ru, ∼0.3 kcal/mol; Rh, ∼0.4 kcal/
mol). This suggests that the stereochemistry does not
determine a preferential formation of one or the other
stereoisomer. It is more likely that the isolation of pure
diastereomers is a result of the more facile crystallization of
one of them.
NMR spectroscopic investigations in different solvents
showed that the prepared complexes have differing stability
in solution. In contrast to the Rh and Ir derivatives, the Ru and
Os complexes are stable in aprotic solvents such as CDCl3 or
CD2Cl2. The
1H and 13C{1H} NMR spectra of the Ru and Os
complexes showed one set of signals, while in the case of Rh
and Ir compounds, additional sets of signals were present
immediately after dissolving of the samples in CD2Cl2 (Figures
S22−S37), with the large majority of the dissolved complexes
remaining intact (>95% for Rh and >85% for Ir).
Metal−chlorido ligand bonds are often labile, and ligand
exchange can occur in H2O, methanol, or DMSO sol-
utions.49−51 Since usually the test compounds are dissolved
in DMSO for biological studies, we investigated the stability of
such solutions by 1H NMR and UV−vis spectroscopy, as well
as ESI-mass spectrometry. The 1H NMR spectra showed that
all complexes undergo changes in DMSO-d6 solutions,
resulting in the formation of a new set of signals (Figures
S5−S8); however, the resulting solutions were stable in the
dark for days. We observed differing kinetics in the chloride/
solvent exchange of the studied complexes for the Ru/Os and
Rh/Ir couples. The Rh complexes undergo an extremely fast
Figure 2. VT-1H NMR spectra of 5b in CD2Cl2.
Figure 3. ORTEP representation of the molecular structures of (a) 3b
and (b) 5a. Atomic displacement parameters are drawn at the 50%
probability level. Hydrogen atoms are represented as fixed-size
spheres and unlabeled for clarity. Counteranions and cocrystallized
solvent have been removed for clarity.
Table 1. Selected Bond Lengths (Å) Found for the
Molecular Structures of Complexes 3b, 4a, 5a, 5b, 6a, and
6b about the Respective Metal Center
bond lengths/Å
compound M−Cl M−Nendo M−NH2
3b 2.3967(12) 2.137(4) 2.104(4)
4aa 2.391(2) 2.137(6) 2.124(7)
5a 2.3962(4) 2.1586(12) 2.1323(14)
5b 2.3949(5) 2.1593(17) 2.1288(18)
6a 2.3943(9) 2.148(3) 2.130(3)
6b 2.3956(8) 2.149(3) 2.131(3)
aFor one of the independent molecules in the unit cell.
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and almost complete chlorido/solvent ligand exchange which
results in the appearance of only one main set of signals in
fresh solution. The other complexes reacted significantly
slower in the order of Os < Ru, Ir < Rh. The ESI-mass
spectra (Figures S9−S12) and UV−vis spectra (Figure S14)
confirmed that the complexes are sufficiently stable in DMSO
solution in the dark, and only minor changes in the UV−vis
spectra were observed, which may be assigned to chlorido/
DMSO ligand exchange.
In methanol solution, the Ir and Ru complexes underwent
very fast cleavage of the M−Cl bonds (ca. 31%), occurring just
after preparation of the solution, while their Os and especially
Rh counterparts were more resistant toward such reactions
with 22% of the Os and 12% of the Rh complex undergoing
chlorido ligand exchange. This process can be suppressed by
the addition of lithium chloride (as saturated solution in
CD3OD) and in the presence of a high concentration of
chloride ions; this reaction is almost completely reversible (for
6b see Figure 4 and Figure S13).
Dulbecco’s Modified Eagle’s Medium (DMEM) consists of
numerous organic compounds which may act as ligands for
organometallics. Therefore, we studied the solution behavior of
the synthesized compounds in DMEM using UV−vis spec-
troscopy, mimicking cell culture conditions by adding the
DMSO solutions of the complexes (100 μM) while keeping
the DMSO concentration as low as 0.5%. The UV−vis spectra
indicated that all compounds reacted within minutes with
DMEM components (Figures S15−S18 and Table S3). On the
basis of the DMEM composition and previously reported data
for Ru complexes,52−54 we selected L-cystine (CysCys) and L-
histidine (His) for further studies. Both substances are
prominent components of DMEM (0.2 mM). UV−vis spectra
and LC-MS analysis of freshly prepared solutions of the
organometallic complexes (100 μM) and the amino acids
(200 μM) revealed that the Ir and Rh complexes afforded a
mixture of organometallic species when incubated with His.
The UV−vis spectra of mixtures of 5a and 6a with His showed
the quick formation of new species (for 5a see Figure S19, for
6a see Figure S20), as was observed for incubation mixtures of
5a and 6a in DMEM (Figures S17 and S18, respectively). The
LC-MS data collected for a freshly prepared mixture of Ir
complex 6a with His (Figure S21) showed singly charged ions
at a retention time of 0.17 min. These ions were detected at m/
z 704.3, 668.3, and 482.2 and assigned to [M − PF6]+, [M −
HCl − PF6]+, and the His adduct [(Cp*)Ir(His) − H]+,
respectively. After 30 min of stirring at RT, two main peaks
were present in the chromatogram. The mass spectrum
collected at 0.17 min featured the same m/z values as before
with the His adduct at m/z 482.2 being the base peak (Figure
S22). A second species eluted at 0.26 min yielded ions at m/z
342.2 assigned to [(R)-2 + H]+. Similar results were obtained
for the Rh complex 5a. A peak eluting at 0.17 min gave ions at
m/z 614.3, 578.3, and 392.2, which corresponded to [M −
PF6]
+ and [M − HCl − PF6]+ and [(Cp*)Rh(His) − H]+
(Figure S23), followed by a second compound eluting at 0.26
min with ions assigned to [(R)-2 + H]+. After 30 min of
stirring of 6a with His, only singly charged ions at m/z 392.2
and 342.2 stemming from the His adduct [(Cp*)Rh(His) −
H]+ and protonated ligand [(R)-2+ H]+ were observed (Figure
S24). Only the Rh complex reacted with cystine and released
(R)-2, as detected by MS at m/z 342.2 for [(R)-2 + H]+,
whereas all other complexes remained unchanged. Interest-
ingly, neither the Ru nor the Os derivatives were found to form
stable complexes with His or cystine during the 30 min
incubation period, and only [M − PF6]+ and [M − HCl −
PF6]
+ ions were detected.
Antiproliferative Activity. A high level of inhibition of
KSP activity may result in significant antiproliferative effects in
cancer cells.55,56 Therefore, the cytotoxicity of (R)-2 and (S)-2
and their organometallic complexes 3a−6a and 3b−6b toward
human colorectal carcinoma (HCT116), hepatocellular
carcinoma (HepG2), large cell lung cancer (NCI-H460),
colorectal adenocarcinoma (SW480 and SW620), and cervical
squamous cell carcinoma (SiHa) cells was studied (Table 2).
The cell lines used exhibited variable sensitivity to the parental
compounds, (R)-ispinesib and (S)-ispinesib ((R)- and (S)-1,
respectively). (R)-1 exhibited high cytotoxicity toward the
majority of cells studied with IC50 values <8 nM for most of
the studied cancer cell lines with the exception for HepG2, for
which the IC50 value was 0.53 ± 0.01 μM. The corresponding
(S)-enantiomer (S)-1 was characterized by significantly lower
cytotoxicity with IC50 values in the high nanomolar or even
Figure 4. 1H NMR spectra (aromatic region) of 6b in methanol-d4 in
the presence of various amounts of lithium chloride: (a) solution of
6b in CD3OD, (b) 6b + 20 μL of LiCl, (c) 6b + 20 μL of LiCl after
24 h, (d) 6b + 40 μL of LiCl, (e) 6b + 90 μL of LiCl, and (f) 6b +
190 μL of LiCl.
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micromolar range. In comparison to the enantiomers of 1, the
ligands (R)- and (S)-2 were much less cytotoxic than the
analogous parent compounds. Metal complexation resulted in
augmented biological activity of the investigated compounds,
in both the (R)- and (S)-series. However, metal complexes of
the (R)-ligands were generally much more active than their (S)
counterparts. The overall antiproliferative properties of the
investigated compounds in the selected cell line panel can be
ranked in the following order: (R)-1 > (S)-1 > 6a > 3a ≈ 4a ≈
5a > (R)-2 > 3b > 4b > 6b > 5b > (S)-2. Metal complexation
did not significantly alter the activity of (R)-2 derivatives in the
cell lines tested, except for moderately elevated effects of the Ir
complex 6a. In contrast, although the antiproliferative potential
of (S)-2 is significantly lower than that of (R)-2, metal
complexation elevated its activity. The Ru and Os complexes
3b and 4b of (S)-2 exerted potent biological effects
demonstrating between 2-fold (3b in SiHa cells) and 9-fold
(4b in HCT116) higher activity than the parent organic ligand,
showing a clear impact of metal coordination.
Considering the individual cell line vulnerability, HCT116
proved to be the most sensitive cell line to the compounds
investigated, including ispinesib. Additionally, all the com-
plexes of (R)-2 were similarly potent in this cell line as the
ligand itself.
KSP Inhibition. Ispinesib is a well established KSP
inhibitor with IC50 values reported to be in the range of
0.5−4.6 nM.57 The ability of the synthesized compounds to
inhibit KSP activity was studied by the ATP hydrolysis assay.
We found that the Rh/Ir complexes 5a, 5b, 6a, and 6b
exhibited higher activity in comparison to the ispinesib-derived
ligands (R)-2 and (S)-2 (Figure 5), even at concentrations as
low as 1 nM. In contrast, the Ru and Os complexes are
significantly less active. Comparison of the Rh and Ir
complexes bearing the (S)-2 or (R)-2 ligands revealed that
the observed KSP inhibitory activity is virtually independent of
their conformation. In contrast, the Ru and Os (R)-2-type
complexes were found to be significantly stronger KSP
inhibitors than analogous (S)-2 complexes, with the former
leading to a maximal inhibition of approximately 40% at
100 nM concentration. These results are especially interesting
in view of the fact that ruthenium complexes of another KSP
inhibitor, monastrol, were shown to exhibit lower KSP
inhibitory activity than the parent compound.58,59
Docking Study. In order to elucidate contrasting structural
features of relevance to protein interaction for the organo-
metallic compounds, molecular modeling was used to
investigate the possible binding mode for the ligands (R)-
and (S)-2 and their half-sandwich complexes 3a−6b as well as
the respective diastereomers 3a′, 3b′, 5a′, and 5b′ to KSP.
While the complexes may undergo ligand exchange in aqueous
solution to form aqua complexes, or in the presence of proteins
to form covalent bonds, for the reason of comparability, we
decided to dock the chlorido complexes. The KSP cocrystal
structure with ispinesib derived from Homo sapiens was
obtained from the Protein Data Bank (PDB ID: 4AP0;
resolution 2.59 Å).60 Co-crystallized ispinesib was removed
and redocked to the allosteric site with excellent docking
overlay (RMSD = 0.356 Å for GoldScore; Table S4 and Figure
S25A). Ispinesib is buried in the allosteric site and displays
numerous interactions with residues of the inhibitor-binding
pocket.61 Both the cocrystallized ligand and its redocked
configuration showed that the benzyl moiety of the ligand is
Table 2. In Vitro Antiproliferative Activity of (R)- and (S)-Ispinesib, (R)-2 and (S)-2 and Their Organometallic Complexes
3a−6a and 3b−6b, Respectively, in Human Cancer Cell Lines (Exposure Time 72 h; Mean IC50 Values ± SD, n = 3)a
IC50 [μM]
compound HepG2 SW620 HCT116 NCI-H460 SW480 SiHa
(R)-1 0.53 ± 0.01 <0.008 <0.008 <0.008 <0.008 <0.008
(S)-1 2.8 ± 0.4 2.5 ± 0.9 0.08 ± 0.04 0.20 ± 0.07 0.86 ± 0.38 0.81 ± 0.27
(R)-2 74 ± 33* 9.0 ± 3.6 0.28 ± 0.19 1.2 ± 0.1 3.8 ± 0.4 4.7 ± 0.6
(S)-2 175 ± 108* ≫30 20 ± 3 36 ± 3 46 ± 3 31 ± 2
3a 63 ± 36* 1.4 ± 0.3 0.55 ± 0.04 1.6 ± 0.3 4.0 ± 0.6 5.1 ± 0.3
3b 12 ± 3 0.94 ± 0.20 3.6 ± 0.1 6.9 ± 0.1 13 ± 1 14 ± 1
4a 72 ± 23* 2.0 ± 0.4 0.66 ± 0.07 2.0 ± 0.2 3.8 ± 0.1 5.5 ± 0.6
4b 45 ± 17* 0.67 ± 0.01 2.3 ± 0.2 5.4 ± 0.2 7.5 ± 1.2 11 ± 1
5a 47 ± 15* 1.0 ± 0.2 0.29 ± 0.03 1.2 ± 0.1 3.7 ± 0.3 4.4 ± 0.04
5b 53 ± 11* 84 ± 33* 18 ± 1 32 ± 1 40 ± 1 27 ± 1
6a 11 ± 2 0.86 (too wide) 0.41 ± 0.05 0.91 ± 0.01 2.9 ± 0.3 3.1 ± 0.2
6b 110 ± 77* 39* (too wide) 14 ± 2 29 ± 3 40 ± 2 26 ± 1
a(*) Over range; (too wide), the curve drops down rapidly so no SD can be calculated.
Figure 5. KSP activity in the presence of increasing concentrations of the ligands (R)-2 and (S)-2 and of their organometallic complexes 3a−6a
and 3b−6b. Data are presented as mean ± SEM, n = 3 or 4 (for controls).
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buried deeply in the hydrophobic part of the pocket, where it
stacks with the Pro137 ring and makes an edge-to-face
interaction with the side chain of Trp127. Moreover, it is
found to be in lipophilic contact with the side chains of
Tyr211, Ala218, Ala133, Glu118, Arg119, Leu160, and Leu214
(Figure S25B). The similarities in the docked configurations to
the one described in the literature23,61−63 and a low RMSD
value suggest the reliability and reproducibility of the docking
protocol.
The spatial orientations and interactions (Tables 3 and S5)
found for (R)- and (S)-2 and their half-sandwich complexes
3a−6b as well as the respective diastereomers 3a′, 3b′, 5a′,
and 5b′ show that the compounds may bind to the same site as
previously reported,60−64 which is suggestive to be related to
their anticancer activity. Both (R)- and (S)-2 show similar
interactions with the protein with the main difference being a
hydrogen bond of the latter to Tyr211 and a slightly higher
GoldScore for the (R) enantiomer.
For the organometallic compounds, in general, the SM,R and
RM,R isomers showed higher predicted scores than the isomers
derived from (S)-2 with the exception of the Rh complex pair
5a′/5b′ (Table 3). While the isostructural compounds 3a and
4a are found in virtually identical positions in the structure,
their diastereomers 3b and 4b behaved very differently, with
the Os complex giving a lower docking score than the Ru
analogue and interaction with a limited number of amino acids
(Table S5). However, these differences have a big impact on
the cytotoxic activity and the KSP inhibition with (R)-2 based
3a and 4a being more potent than 3b and 4b in both assays.
Surprisingly, the observations were very different for the Rh
and Ir complexes. While the isomers 5a/5b and 6a/6b follow a
similar pattern in the cytotoxicity assay, they are equally potent
in inhibiting KSP independent of the configuration of the
ligand or the metal center. This trend is also reflected in the
GoldScores found for these compounds, which are very similar
but significantly lower than those found for the Ru and Os
complexes of (R)-2. This suggests that for the latter classes of
compounds KSP may not be the target, but their cytotoxic
potential is exhibited through other means.
The docked configurations of Rh complexes 5a and 5b into
the binding site are shown in Figure 6. For 5a, the Cp* moiety
Table 3. GoldScores for the Docking Scores of (R)- and (S)-
2 and Their Half-Sandwich Complexes 3a−6b As Well As
the Respective Diastereomers 3a′, 3b′, 5a′, and 5b′,
Dependent on the Chiral Configuration at the Metal Center
and Ligand
GoldScore
compounds (R) (S)
2 61.5 58.8
configuration (SM,R) (RM,S) (RM,R) (SM,S)
compound a b a b
3 78.8 59.1
4 78.9 52.7
5 59.6 59.1
6 60.0 56.3
3′ 54.4 51.6
5′ 49.0 50.4
Figure 6. Docked configurations of (A) 5a and (B) 5b into the binding site of KSP (PDB ID: 4AP0) using GoldScore. The hydrogen bond
interaction is depicted as a green line, and lipophilic contacts are shown as purple dashed lines.
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is embedded deeply in the hydrophobic pocket formed by
Leu214, Ala133, and Trp127 (Figure 6A). The quinazolinyl
moiety interacts with parts of the side chain of Arg119, and the
chlorine substituent of the quinazolinyl moiety sits in another
mostly hydrophobic pocket formed by the side chain of Ala133
and Pro137. The benzyl moiety of the ligand is not inserted
into the active site pocket and is more exposed to the aqueous
phase, especially when compared to 3a and 4a, which gave
much higher docking scores in a similar range to ispinesib
(Table S4). However, the isopropyl group is only partly buried
and interacting with parts of the side chains of Tyr211 and
Ala218 (Figure 6A). Upon docking of the 5b isomer, the ring
systems are “flipped” relative to 5a (Figure 6B), and in this
case the Cp* ligand is more exposed to the aqueous phase. The
carbonyl group of the quinazolinyl moiety exhibited hydrogen
bonding with the side chain of Arg119. The benzyl group sits
deep in the hydrophobic pocket and forms an edge-to-face
stacking interaction with the side chains of Ala133 and Arg119.
The isopropyl group is embedded deep and orientated toward
the binding pocket of ispesinib.
In addition to the diastereomers characterized by X-ray
diffraction analysis, we docked diastereomeric structures to 3a,
3b, 5a, and 5b, i.e., 3a′, 3b′, 5a′, and 5b′ (Tables 3 and S5), to
investigate the impact of the π-bound ligand and of chirality on
the docking behavior. Comparison of the GoldScores of
isostructural 3a/4a and 5a′ shows that the Ru- and Os(cym)
complexes resulted in much higher scores than their Rh(Cp*)
counterpart. The effect was found to be less pronounced for
the complexes featuring (S)-2, but the trend is the same. In
both cases, the structures of the complexes were orientated
very differently for the docking result, as they were when
comparing 5a/6a with 3a′ and 5b/6b with 3b′.
Overall, there are significant differences in the docking
results for the different isomers of the organometallics both in
terms of orientation but also in terms of their interactions with
the protein, which may have an impact on their modes of
action. This is also supported by the biological data collected
for the compound classes, under the limitations of docking as
outlined above regarding the possibility of chlorido/aqua
ligand exchange and/or coordination to donor atoms of the
protein. The obtained results correlate with the experimental
inhibitor activity of KSP only in discriminating of the
stereochemistry of ligand 2 but do not correlate with
distinguishing of the organometallic moieties.
ROS Generation. It is often postulated that organometallic
complexes induce oxidative stress in cancer cells.31 Therefore,
we studied the generation of reactive oxygen species (ROS)
induced by complexes 3a−6b in SW620 and HepG2 cells,
differing in sensitivity toward the investigated compounds,
using the dihydrorhodamine 123 (DHR123) oxidation assay
(Figure 7). Surprisingly, the overall pattern of DHR123
oxidation was similar between these two cell lines, indicating
that the redox balance disturbance is independent of the
antiproliferative potential of the compounds studied. It must
be noted, however, that both osmium complexes consistently
decreased the oxidation rate of DHR123 compared to the
control. DHR123 is considered a nonspecific reactive oxygen/
nitrogen species indicator, and therefore these results suggest
that either some intracellular source of ROS is inhibited by the
investigated compounds or the compounds themselves exhibit
some antioxidant activity. Such activity was demonstrated, for
example, for Ni(II) quinazoline complexes and Mn-porphyrins,
acting as low molecular weight superoxide dismutase
mimics.65,66
To test these hypotheses, we performed a robust ABTS
[2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic acid)] radical
cation reduction assay.67 We were able to demonstrate that
both Os (4a and 4b) and to a lesser extent also Ru (3a and 3b)
complexes exhibited antioxidant properties (Figure 8). It can
be therefore inferred that the osmium complexes add to the
antioxidant pool of the cell and thus reduce the DHR123
oxidation rate.
Cellular Accumulation. The antiproliferative potential of
anticancer agents is, at least to some extent, dependent on their
cellular accumulation. Therefore, we aimed to determine the
amount of the respective metal accumulated in SW620 cancer
cells by ICP-MS following exposure to the synthesized
complexes. The choice of the cell line was dictated by the
facts that (i) it responds well to ispinesib (Table 2) and (ii) it
does not express any of the major multidrug resistance proteins
that could alter the influx kinetics of the investigated
compounds.68 However, this experimental approach based on
the sole metal measurement does not allow for discrimination
between the metal complex accumulated inside the cell or
bound to the cell surface. In this case, there is no clear
correlation between cytotoxic/cytostatic effects and the
determined metal concentration. For all compounds, the
amount of metal detected was highest after 1 h and declined
over time (Figure 9). The Os complexes reached a significantly
Figure 7. Ability to induce ROS generation in SW620 (left, A) and HepG2 (right, B) cells after 4-h exposure to complexes 3a−6b (1 μM). CTRL
(expressed as 100%), cells in DMEM complete culture medium; DMSO, cells in DMEM complete culture medium with addition of DMSO (0.1%)
as a solvent control; VER, cells in DMEM complete culture medium with addition of 10 μM verapamil to exclude potential impact of ABCB1
activity on the intracellular rhodamine 123 level. Results are expressed as mean ± SEM, n = 3. Asterisks denote statistical significance against
respective solvent controls (P < 0.01, one-way ANOVA followed by post hoc Tukey test).
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higher concentration than the corresponding Ru complexes
(up to ca. 16 nmol Os/mg cellular protein), while the more
cytotoxic 5b and 6b complexes were detected in concen-
trations up to 1.4 and 3.4 nmol of metal/mg protein,
respectively. Interestingly, for complexes bearing (S)-2 as the
ligand, slightly higher values were found compared to the more
active derivatives of (R)-2. As mentioned before, Ir and,
especially, Rh complexes tend to release (R)- and (S)-2 when
incubated with histidine and/or cystine, which presumably
may also occur in a culture medium. Metal species may enter
the cells by the ligand conveyor mechanism similar to that
postulated for phosphine gold complexes in the case of
auranofin69 but may be then readily exported from the
cytoplasm, presumably with glutathione, as was demonstrated
for cisplatin.70 This would explain the observations in terms of
detected low metal content in cell uptake studies, high
antiproliferative activity, and excellent KSP inhibitory potency.
■ CONCLUSIONS
Two series of organoruthenium, -osmium, -rhodium, and
-iridium complexes with the ligands (R)- and (S)-2-(1-amino-
2-methylpropyl)-3-benzyl-7-chloroquinazolin-4(3H)-one were
synthesized. The series differed in their antiproliferative
potentials, with the complexes of the (R)-configured ligands
exerting significantly stronger biological effects with IC50 values
in the high nanomolar range for the most susceptible cell line
tested as compared to low to medium micromolar activity for
the corresponding (S)-analogues. Interestingly, the effect of the
metal center on the antiproliferative potential of the
investigated compounds was rather moderate. On the other
hand, introduction of a metal center significantly affected the
anti-/prooxidative properties, cellular accumulation, and
inhibitory effects on KSP. The Os and Ru complexes inhibited
ROS formation, avidly accumulated in cells, and exerted low to
moderate effects on KSP activity. On the other hand, the Rh
and Ir complexes were potent KSP inhibitors, despite the low
stability of the Rh complexes which warrants further
investigation. The level of their cellular accumulation/binding
was an order of magnitude lower, and their effects on
intracellular reactive oxygen species level were negligible.
These observations may be at least partially explained by
differences in the susceptibility of the metal complexes for
ligand exchange reaction.
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